Here is a review paper written by a researcher in Institute of Chemistry, Slovak Academy of Sciences, 845 38 Bratislava, Slovakia about the role of glycans in human.
https://www.mdpi.com/1420-3049/30/13/2678
In this paper, therapeutic potentials targeting glycan-glycan-binding proteins (GBPs), such as selectins, galectins, and Siglecs, are summarized as follows.
- 1) Inhibition of GBP–glycan interactions, for example, Uproleselan (Glycomimetics)
- 2) Monoclonal antibodies targeting glycans, for example, Dinutuximab/Unituxin (National Cancer Institute) and Naxitamab/Danyelza (Memorial Sloan Kettering Cancer Center) to target ganglioside GD2
- 3) Carbohydrate-based vaccines against pathogens and cancer, for example, carbohydrate-based vaccine against the bacteria Haemophilus influenzae type b (Pentacel from Sanofi Pasteur, Hiberix, Merck and Co.), and as vaccines against cancer, Theratope (Biomira), GM2-KLH (Memorial Sloan Kettering Cancer Center), OPT-822 (OBI Pharma), and Racotumomab (Molecular Immunology Center in Havana) targeting sTn antigen, ganglioside GM2, glycolipid Globo H, and ganglioside GM3
- 4) Immune checkpoint inhibitor (ICI)
- 5) Altering the biosynthesis of carbohydrate determinants with carbohydrate processing inhibitors (CPIs)
Just for your information.
